{"id":"NCT05704725","sponsor":"Amgen","briefTitle":"A Study to Evaluate ABP 938 and Aflibercept (Eylea®) in Participants With Chorioretinal Vascular Disease (CVD)","officialTitle":"An Open Label, Two-Arm Study in Subjects With Chorioretinal Vascular Disease to Evaluate ABP 938 and Aflibercept (Eylea®) in a Prefilled Syringe","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2023-01-23","primaryCompletion":"2023-02-17","completion":"2023-03-24","firstPosted":"2023-01-30","resultsPosted":"2025-02-14","lastUpdate":"2025-02-14"},"enrollment":49,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Chorioretinal Vascular Disease"],"interventions":[{"type":"DRUG","name":"ABP 938","otherNames":["PAVBLU™"]},{"type":"DRUG","name":"Aflibercept","otherNames":["Eylea®"]}],"arms":[{"label":"ABP 938","type":"EXPERIMENTAL"},{"label":"Aflibercept","type":"EXPERIMENTAL"}],"summary":"The primary objective of this study is to is to assess the ability of retina specialists to successfully administer, via an intravitreal (IVT) injection, a 2 mg dose of ABP 938, using the ABP 938 aflibercept prefilled syringe (PFS), compared to a 2 mg dose of aflibercept using the aflibercept PFS.","primaryOutcome":{"measure":"Percentage of IVT Injections Successfully Administered","timeFrame":"Day of IVT injection (study day 1)","effectByArm":[{"arm":"ABP 938","deltaMin":100,"sd":null},{"arm":"Aflibercept","deltaMin":100,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":16},"locations":{"siteCount":4,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":["http://www.amgentrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":32},"commonTop":["Vitreous detachment","Diarrhoea","Arthralgia"]}}